Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

OBJECTIVE: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. METHODS: In this phase 3, multicentre, placebo-controlled tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher, Rahman, Proton, Kavanaugh, Arthur, McInnes, Iain B, Puig, Lluis, Li, Shu, Wang, Yuhua, Shen, Yaung-Kaung, Doyle, Mittie K, Mendelsohn, Alan M, Gottlieb, Alice B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033144/
https://www.ncbi.nlm.nih.gov/pubmed/24482301
http://dx.doi.org/10.1136/annrheumdis-2013-204655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033144/
https://www.ncbi.nlm.nih.gov/pubmed/24482301
http://dx.doi.org/10.1136/annrheumdis-2013-204655

Ejemplares similares